BERKELEY HEIGHTS, N.J., Jan. 18 /PRNewswire-FirstCall/ -- Genta Incorporated announced today the appointment of Dr. Per I. Lindell, Sc.D., as Vice President of Business Development. At Genta, Dr. Lindell will have broad responsibility for expanding the Company's worldwide business development activities, including partnering negotiations for the Company's lead anticancer product, Genasense(R) (oblimersen sodium) Injection, as well as in-licensing and acquisition of new products and technology.
"In addition to the Genasense partnering activities, Genta is extremely interested in acquiring new products in oncology that will extend our reach in DNA/RNA-based Medicines and small molecules," commented Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta. "Dr. Lindell's background as both a scientist and a business executive make him an ideal candidate to lead these efforts on our behalf, and we look forward to his contributions as part of the Genta team."
Biographical sketch on Per I. Lindell, Sc.D.:
Dr. Lindell has nearly 20 years of experience in the pharmaceutical industry. He was most recently Vice President, Corporate Development, at Metaphore Pharmaceuticals. Until 2003, he was Vice President, Business Development, at Avalon Pharmaceuticals in Maryland. From 1998 to 2001, Dr. Lindell was Senior Director, Business Development, New Product Launches and Strategic Planning, at Knoll Pharmaceuticals, a division of BASF. He had previously served as a management consultant with the Boston Consulting Group and Arthur D. Little, and as a Research Engineer at Pharmacia AB in Uppsala, Sweden. Dr. Lindell received a Doctor of Science degree in Biochemical Engineering from the Massachusetts Institute of Technology in Cambridge and a Master of Science degree in Chemical Engineering from the Royal Institute of Technology in Stockholm.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.
Genta IncorporatedCONTACT: Investor Relations - Tara Spiess of TS Communications Group, LLC,spiess@biotechirpr.com, +1-914-921-5900; Media Relations - Greg Tiberend ofRichard Lewis Communications, Inc., +1-212-827-0020, both for GentaIncorporated
Web site: http://www.genta.com/
